Af­ter pan­dem­ic-re­lat­ed dis­rup­tions, will 2021 bring about a re­newed spot­light on R&D? A CFO sur­vey says yes

Though ven­ture cap­i­tal fund­ing swelled dur­ing the Covid-19 pan­dem­ic and led to a mas­sive boom, oth­er as­pects of the health cri­sis neg­a­tive­ly af­fect­ed the in­dus­try, such as re­stric­tions on lab ca­pac­i­ties and tri­al-site in­ter­rup­tions. But, ac­cord­ing to a new sur­vey, a ma­jor­i­ty of life sci­ences CFOs be­lieve 2021 will be a re­bound year.

Near­ly sev­en in 10 CFOs say the new year will bring a re­dou­bled fo­cus on R&D ef­forts across the in­dus­try, per the 2021 BDO Life Sci­ences CFO Out­look Sur­vey, with 69% fore­cast­ing a rev­enue in­crease for their com­pa­nies. Ad­di­tion­al­ly, 81% ex­pect to see prof­itabil­i­ty rise, while 61% see an eco­nom­ic re­cov­ery in the fu­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER